Patents by Inventor Bertrand L Chenard

Bertrand L Chenard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20250034143
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: February 21, 2024
    Publication date: January 30, 2025
    Applicant: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Therapeutic compounds and compositions
    Patent number: 12152014
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: November 26, 2024
    Assignee: eXlthera Pharmaceuticals, Inc.
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS
    Publication number: 20240124413
    Abstract: Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.
    Type: Application
    Filed: April 13, 2023
    Publication date: April 18, 2024
    Inventors: Xinyuan WU, Bertrand L. CHENARD, Nili Claudia SCHUTZ, Dov TERKIELTAUB
  • Substituted xanthines and methods of use thereof
    Patent number: 11958854
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: April 16, 2024
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20240059670
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: February 17, 2023
    Publication date: February 22, 2024
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • Compounds and compositions for use in treating skin disorders
    Patent number: 11807621
    Abstract: Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: November 7, 2023
    Assignee: KAMARI PHARMA LTD.
    Inventors: Xinyuan Wu, Bertrand L. Chenard, Nili Claudia Schutz, Dov Terkieltaub
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20230270731
    Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
    Type: Application
    Filed: April 19, 2023
    Publication date: August 31, 2023
    Applicant: eXIthera Pharmaceuticals, Inc.
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Philipp Erik Schneggenburger, Matteo Placido Placidi, Wendy Mercer Geil, Gonto Johns, III
  • Therapeutic compounds and compositions
    Patent number: 11691962
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: July 4, 2023
    Assignee: EXITHERA PHARMACEUTICALS, INC.
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20230040259
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 9, 2023
    Applicant: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS
    Publication number: 20220332697
    Abstract: Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.
    Type: Application
    Filed: January 28, 2021
    Publication date: October 20, 2022
    Inventors: Xinyuan WU, Bertrand L. CHENARD, Nili Claudia SCHUTZ, Dov TERKIELTAUB
  • Substituted xanthines and methods of use thereof
    Patent number: 11208409
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: December 28, 2021
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210361634
    Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Philipp Erik Schneggenburger, Matteo Placido Placidi, Wendy Mercer Geil, Gonto Johns., III
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210261524
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable salts thereof and compositions and methods of use thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 26, 2021
    Inventors: Neil J. HAYWARD, Bertrand L. CHENARD, Yuelian XU, Roberta L. DOROW, Michael E. MATISON, Alexander KOLCHINSKI, Richard FORNICOLA
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210253550
    Abstract: Provided herein are compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and compositions.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 19, 2021
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Roberta L. Dorow, Michael E. Matison, Alexander Kolchinski, Richard Fornicola
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210188812
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10519158
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 31, 2019
    Assignee: Eli Lilly and Company
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20190330212
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: December 28, 2018
    Publication date: October 31, 2019
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20190322667
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: April 29, 2019
    Publication date: October 24, 2019
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190315711
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10428072
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 1, 2019
    Assignee: Eli Lilly and Company
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans